Welcome to our dedicated page for Jupiter Wellness news (Ticker: jupw), a resource for investors and traders seeking the latest updates and insights on Jupiter Wellness stock.
Jupiter Wellness, Inc. (JUPW) drives innovation in CBD-infused therapeutic products, from sun care lotions to advanced dermatological solutions. This page serves as the definitive source for verified company updates, offering stakeholders timely access to official announcements.
Find curated press releases covering new product launches across Canisun, Caniskin, and CanidermRx brands, regulatory milestones in the CBD sector, financial disclosures, and strategic partnerships. Each update is sourced directly from Jupiter Wellness to ensure accuracy and compliance with financial reporting standards.
Investors and industry observers can use this resource to monitor JUPW's growth in the competitive wellness market. Bookmark this page for efficient tracking of the company's advancements in CBD research and consumer product development.
Jupiter Wellness (NASDAQ:JUPW) has priced a public offering of 11,066,258 shares of common stock at $2.79 per share, along with 540,884 shares from selling stockholders and warrants for 11,607,142 shares. The offering's gross proceeds are estimated at $32.5 million, potentially increasing to $37.4 million if the underwriters' over-allotment option is fully exercised. The deal is expected to close on July 26, 2021. Aegis Capital Corp. serves as the sole book-running manager.
Jupiter Wellness (NASDAQ:JUPW) has entered a multi-year agreement with Rigour International for exclusive distribution of its products in Mainland China and non-exclusive rights in Hong Kong, Korea, and Southeast Asia. This partnership aims to enhance the reach of Jupiter's skincare brands, including Comfort Cream and Canisun Sunscreen, to over 300 million consumers in Asia. Jupiter Wellness focuses on developing skin care therapeutics targeting conditions like eczema and skin cancer.
Jupiter Wellness (NASDAQ:JUPW) has appointed Dr. Andy Goren to its Scientific Advisory Board, enhancing its dermatological expertise. Dr. Goren has over 20 years of experience in clinical research and has developed several firsts in dermatology. His role will focus on advancing clinical programs in eczema, burns, and actinic keratosis. Dr. Goren's extensive network in dermatology is expected to facilitate the development and commercialization of Jupiter's skincare therapeutics.
Jupiter Wellness (NASDAQ:JUPW) announced a head-to-head clinical trial comparing its JW-100 lotion against Eucrisa (crisaborole ointment 2%) for eczema treatment. The Phase III trial intends to evaluate the efficacy of JW-100, a non-steroidal lotion containing cannabidiol, in adult patients. Previous trials indicated significant improvement in eczema symptoms for 50% of participants using JW-100. The company aims to confirm these findings in a larger population and potentially commercialize JW-100 for both over-the-counter and prescription markets.
Jupiter Wellness (NASDAQ:JUPW) announced an exclusive licensing agreement for Photocil, a patented topical cream effective against Psoriasis, Vitiligo, and Atopic Dermatitis. The deal with Applied Biology allows Jupiter to use associated intellectual property for manufacturing and marketing in the U.S. Photocil, already available in Europe, provides a safer alternative to traditional phototherapy. Dr. Glynn Wilson emphasized plans to register the product with the FDA and start marketing promptly.
Jupiter Wellness, Inc. (NASDAQ:JUPW) announced a peer-reviewed publication detailing the efficacy of JW-100, a proprietary lotion for treating atopic dermatitis. The double-blind, placebo-controlled study involved 57 patients and showed that the JW-100 group achieved a statistically significant reduction in the Investigator's Static Global Assessment (ISGA) score (p = 0.042). Notably, 50% of JW-100 patients reached an ISGA score of clear or almost clear, compared to 20% in the CBD-only group. The company plans to file with the FDA in Q3 2021 for further development of JW-100.
Jupiter Wellness (NASDAQ:JUPW) has entered into a licensing agreement with the Oklahoma Medical Research Foundation for two patents related to the use of aspartame in treating Contact Dermatitis. This deal grants Jupiter exclusive worldwide rights to the patents, enhancing its product offerings. The company has also filed a new patent for a combination of CBD and aspartame aimed at various skin conditions, including eczema. Notably, a clinical trial showed significant improvement in atopic dermatitis patients using JW-100, a topical formulation with CBD and aspartame.
Jupiter Wellness, Inc. (NASDAQ:JUPW) has provided an update on its clinical pipeline involving CBD-based therapeutics, announcing the commencement of patient enrollment for its JW-200 treatment for Actinic Keratosis, aiming for a Q4 2021 study completion. The company is also recruiting for JW-300, designed for first-degree burns, with topline data expected in Q4 2021. Jupiter is preparing for an FDA IND meeting for JW-100, targeting eczema. Additionally, JW-400 for herpes cold sores is set for recruitment in Q4 2021. Jupiter's strategic focus targets significant market opportunities, seeking to address unmet clinical needs.
Jupiter Wellness, Inc. (NASDAQ:JUPW) has signed a non-binding Letter of Intent to acquire 51% of JustCBD for $30 million in cash. JustCBD reported approximately $28 million in revenue for 2020 (unaudited). The acquisition could lead to a total purchase price of $60 million if Jupiter exercises a put option for the remaining 49%. The deal includes a 3-year management agreement for JustCBD's management team and board representation. Closing is contingent on due diligence, financing, and regulatory approvals.
Jupiter Wellness, Inc. (NASDAQ:JUPW) has appointed key executives to enhance its leadership: Dr. Glynn Wilson as Chief Science Officer, Rich Miller as Chief Compliance Officer, and Ryan Allison as Chief Operating Officer. The company continues to expand its CBD-based wellness product line, now featuring 40 products across seven brands. Jupiter is advancing its clinical pipeline with one indication nearing FDA IND application and three in Phase 1 studies. With a focus on eczema and other skin conditions, the company targets significant market opportunities in the CBD sector, estimated at $10 billion globally.
